Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

Publication Type:

Journal Article

Source:

Journal of the National Cancer Institute, Volume 102, Issue 22, p.1706-15 (2010)

Keywords:

2010, Aged, Aged, 80 and over, Anticarcinogenic Agents, Bone Density, Bone Density Conservation Agents, Breast Neoplasms, Carcinoma, Ductal, Breast, Case-Control Studies, Center-Authored Paper, Double-Blind Method, estradiol, Female, Fractures, Bone, Humans, Incidence, Mammography, Middle Aged, Odds Ratio, Osteoporosis, Postmenopausal, Primary Prevention, Public Health Sciences Division, Pyrrolidines, Receptors, Estrogen, Risk Assessment, Selective Estrogen Receptor Modulators, Sex Hormone-Binding Globulin, Tetrahydronaphthalenes, Treatment Outcome, Tumor Markers, Biological, United States

Abstract:

Currently available selective estrogen receptor modulators reduce the risk of breast cancer, but they are not widely used. In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, lasofoxifene was shown to reduce the risk of estrogen receptor-positive (ER+) breast cancer, nonvertebral and vertebral fractures, coronary artery disease, and stroke, but the effects on total breast cancer (invasive and ductal carcinoma in situ, ER+ and estrogen receptor-negative [ER-]) and ER+ invasive breast cancer are unknown.